Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases.

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is

Novo Nordisk har indgået en aftale om at købe lægemidlet Zaltenibart af det amerikanske selskab Omeros. Det oplyser Novo i en børsmeddelelse.

Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.

— Phase 3 Data Needed for BLA Submission Expected in the Fourth Quarter 2026 — SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP-3, the key and …

Omeros initiates global Phase 3 trials for zaltenibart in PNH, offering 8-week dosing advantage. Phase 2 showed promising results in $3.8B rare disease market.

Omeros' zaltenibart shows promising efficacy in Phase 2 PNH trial with sustained hemoglobin improvements. Phase 3 trials set for 2025 with optimized dosing regimen.